Pharmacokinetic study of rifabutin in HIV-1-positive Japanese individuals

Pharmacokinetic study of rifabutin in HIV-1-positive Japanese individuals - Rifabutin PK study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001102

Enrollment

Registered

2008-03-28

Start date

2008-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycobacteriosis in HIV-positive individuals

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HIV-positive individuals who require anti-Mycobacterial therapy including rifabutin and are obtained informed concents.

Exclusion criteria

Exclusion criteria: Those who have recieved rifabutine within previous 28 days before study enrollment or who are suspected to have allergy for rifabutin.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters: Cmax, Tmax, AUC, t1/2.	—

Countries

Japan

Contacts

Public ContactJunko Tanuma

International Medical Center of Japan AIDS Clinical Center

03-3202-7181

Outcome results